Cited 11 times in
Risk Reclassification With Coronary Computed Tomography Angiography-Visualized Nonobstructive Coronary Artery Disease According to 2018 American College of Cardiology/American Heart Association Cholesterol Guidelines (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes : An International Multicenter Registry [CONFIRM])
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장혁재 | - |
dc.date.accessioned | 2019-12-18T00:37:15Z | - |
dc.date.available | 2019-12-18T00:37:15Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173141 | - |
dc.description.abstract | The 2018 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol management guideline recommends risk enhancers in the borderline-risk and statin recommended/intermediate-risk groups. We determined the risk reclassification by the presence and severity of coronary computed tomography angiography (CCTA)-visualized coronary artery disease (CAD) according to statin eligibility groups. Of 35,281 individuals who underwent CCTA, 1,303 asymptomatic patients (age 59, 65% male) were identified. Patients were categorized as low risk, borderline risk, statin recommended/intermediate risk or statin recommended/high risk according to the guideline. CCTA-visualized CAD was categorized as no CAD, nonobstructive, or obstructive. Major adverse cardiovascular events (MACE) were defined as a composite outcome of all-cause mortality, nonfatal myocardial infarction, and late coronary revascularization (>90 days). We tested a reclassification wherein no CAD reclassifies downward, and the presence of any CAD reclassifies upward. During a median follow-up of 2.9 years, 93 MACE events (7.1%) were observed. Among the borderline-risk and statin-recommended/intermediate-risk groups eligible for risk enhancers, the presence or absence of any CCTA-visualized CAD led to a net increase of 2.3% of cases and 22.4% of controls correctly classified (net reclassification index [NRI] 0.27, 95% CI 0.13 to 0.41, p = 0.0002). The NRI was not significant among low- or statin-recommended/high-risk patients (all p >0.05). The presence or absence of CCTA-visualized CAD, including both obstructive and nonobstructive CAD, significantly improves reclassification in patients eligible for risk enhancers in 2018 ACC/AHA guidelines. Patients in low- and high-risk groups derive no significant improvement in risk reclassification from CCTA. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Excerpta Medica | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Risk Reclassification With Coronary Computed Tomography Angiography-Visualized Nonobstructive Coronary Artery Disease According to 2018 American College of Cardiology/American Heart Association Cholesterol Guidelines (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes : An International Multicenter Registry [CONFIRM]) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Donghee Han | - |
dc.contributor.googleauthor | Ashley Beecy | - |
dc.contributor.googleauthor | Khalil Anchouche | - |
dc.contributor.googleauthor | Heidi Gransar | - |
dc.contributor.googleauthor | Patricia C. Dunham | - |
dc.contributor.googleauthor | Ji-Hyun Lee | - |
dc.contributor.googleauthor | Stephan Achenbach | - |
dc.contributor.googleauthor | Mouaz H. Al-Mallah | - |
dc.contributor.googleauthor | Daniele Andreini | - |
dc.contributor.googleauthor | Daniel S. Berman | - |
dc.contributor.googleauthor | Jeroen J. Bax | - |
dc.contributor.googleauthor | Matthew J. Budoff | - |
dc.contributor.googleauthor | Filippo Cademartiri | - |
dc.contributor.googleauthor | Tracy Q. Callister | - |
dc.contributor.googleauthor | Hyuk-Jae Chang | - |
dc.contributor.googleauthor | Kavitha Chinnaiyan | - |
dc.contributor.googleauthor | Bnjamin J.W. Chow | - |
dc.contributor.googleauthor | Ricardo C. Cury | - |
dc.contributor.googleauthor | Augustin DeLago | - |
dc.contributor.googleauthor | Gudrun Feuchtner | - |
dc.contributor.googleauthor | Martin Hadamitzky | - |
dc.contributor.googleauthor | Joerg Hausleiter | - |
dc.contributor.googleauthor | Philipp A. Kaufmann | - |
dc.contributor.googleauthor | Yong-Jin Kim | - |
dc.contributor.googleauthor | Jonathon A. Leipsic | - |
dc.contributor.googleauthor | Erica Maffei | - |
dc.contributor.googleauthor | Hugo Marques | - |
dc.contributor.googleauthor | Pedro de Araújo Gonçalves | - |
dc.contributor.googleauthor | Gianluca Pontone | - |
dc.contributor.googleauthor | Gilbert L. Raff | - |
dc.contributor.googleauthor | Ronen Rubinshtein | - |
dc.contributor.googleauthor | Todd C. Villines | - |
dc.contributor.googleauthor | Yao Lu MSc | - |
dc.contributor.googleauthor | Jessica M. Peña | - |
dc.contributor.googleauthor | Leslee J. Shaw | - |
dc.contributor.googleauthor | James K. Min | - |
dc.contributor.googleauthor | Fay Y. Lin | - |
dc.identifier.doi | 10.1016/j.amjcard.2019.07.045 | - |
dc.contributor.localId | A03490 | - |
dc.relation.journalcode | J00071 | - |
dc.identifier.eissn | 1879-1913 | - |
dc.identifier.pmid | 31547994 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0002914919308768 | - |
dc.contributor.alternativeName | Chang, Hyuck Jae | - |
dc.contributor.affiliatedAuthor | 장혁재 | - |
dc.citation.volume | 124 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1397 | - |
dc.citation.endPage | 1405 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOLOGY, Vol.124(9) : 1397-1405, 2019 | - |
dc.identifier.rimsid | 63612 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.